Citalopram Tablet 10mg (Escitalopram Oxalate)

Adult dosage

Safety has not been established for doses exceeding 20mg per day. This drug is administered once daily in the morning or evening, without regard to meals. 1) Adults (1) Major depressive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased up to a maximum of 20mg per day. If the dose of this drug is to be increased to 20mg, the increase should be made at intervals of at least 1 week. In general, 2-4 weeks are needed for antidepressant effects to become apparent. Even after symptoms have resolved, at least 6 months of drug therapy is needed to ensure a therapeutic effect. (2) Panic disorder with or without agoraphobia: The recommended initial dose is 5mg per day for 1 week, followed by an increase to 10mg per day. Depending on the patient's response, the dose may be increased up to a maximum of 20mg per day. The maximum effect appears after approximately 3 months. The safety and efficacy of long-term administration of this drug for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reevaluate each patient to determine the need for continued treatment. (3) Social anxiety disorder: The usual dose is 10mg once daily. In general, 2-4 weeks are needed for symptoms to improve. Thereafter, depending on the patient's response, the dose may be reduced to 5mg per day or increased up to a maximum of 20mg per day. Social anxiety disorder is a condition with a chronic course, and continued treatment for 12 weeks is recommended to ensure a therapeutic effect. Long-term treatment of patients who respond has been studied for 6 months and should be considered on an individual patient basis to prevent relapse. The usefulness of long-term treatment should be reevaluated regularly. Social anxiety disorder is a well-defined diagnostic term for a specific disorder and should not be confused with excessive shyness. Drug therapy should be given only when social anxiety disorder significantly interferes with occupational and social activities. Drug therapy has not been compared with cognitive behavioral therapy. Drug therapy is one part of an overall treatment strategy. (4) Generalized anxiety disorder: The initial dose is 10mg once daily. Depending on the patient's response, the dose may be increased up to a maximum of 20mg per day after at least 1 week of treatment. A long-term treatment trial was conducted in patients who responded to 12 weeks of open-label treatment, with 20mg per day administered for at least 6 months. The physician should regularly reevaluate the usefulness of long-term treatment with this drug for each patient. (5) Obsessive-compulsive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased up to a maximum of 20mg per day. A long-term treatment trial was conducted in patients who responded to 16 weeks of open-label treatment, with 10mg or 20mg per day administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition, and treatment should be continued for a sufficient period to ensure recovery of symptoms. If this drug is administered long term, the usefulness and dosage should be regularly reevaluated for each patient. 2) Patients with renal impairment No dosage adjustment is necessary in patients with mild or moderate renal impairment. Caution is required in patients with severe renal impairment (CLCR < 30㎖/min). 3) Patients with hepatic impairment An initial dose of 5mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased up to 10mg per day. 4) Discontinuation of treatment When discontinuing this drug, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. 5) Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this drug, an interval of at least 14 days must be allowed. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 14 days must have elapsed after discontinuing this drug. 6) Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue preparations should not start this drug because of the increased risk of serotonin syndrome. Administration should be considered for patients who require treatment for a more urgent psychiatric condition, including hospitalization or other interventional procedures. It may be necessary to urgently administer linezolid or an intravenous methylene blue preparation to a patient already receiving this drug. If no alternative to linezolid or an intravenous methylene blue preparation is available and the benefits of treatment with linezolid or an intravenous methylene blue preparation are judged to outweigh the risk of serotonin syndrome in a particular patient, this drug may be discontinued immediately and linezolid or an intravenous methylene blue preparation administered. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or an intravenous methylene blue preparation, or until 24 hours after the last dose, whichever occurs first. Treatment with this drug may be resumed 24 hours after the last dose of linezolid or an intravenous methylene blue preparation. The risk associated with methylene blue preparations administered by non-intravenous routes (oral tablets or local injection), or with this drug administered intravenously at a dose of 1mg/kg or less, is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is an antidepressant used to treat psychiatric conditions such as major depression. Special care is needed for children, adolescents, and young adults aged 18 to 24, as there may be an increased risk of suicidal thoughts or behaviors during treatment. This medication can cause serious side effects, including serotonin syndrome, when used in combination with certain medicines; therefore, patients taking MAO inhibitors or pimavanserin should not use it. Patients with glaucoma or a history of glaucoma should be cautious, as this medication can dilate pupils and increase intraocular pressure. During the first 1-2 weeks of treatment, side effects such as anxiety, insomnia, dizziness, and nausea may frequently occur, but most symptoms will alleviate over time. Additionally, this medication may affect heart rhythm, so caution is necessary for patients with a prolonged QT interval or those taking related medications. While taking this medication, changes in mental state such as suicidal thoughts or behaviors, aggression, and symptoms of anxiety may occur, so careful monitoring by patients and caregivers is essential. Sudden discontinuation of the medication may trigger withdrawal symptoms such as dizziness, anxiety, and sleep disturbances, so the dose should be gradually reduced under a doctor's guidance. Women who are pregnant or breastfeeding should consult a doctor before using this medication, as it may affect the newborn. It is recommended that elderly patients start with a lower initial dose, and those with impaired liver or kidney function should also be cautious. Caution is advised when driving or operating machinery, so it is best to check the condition after taking the medication before engaging in these activities. In case of overdose, symptoms may include central nervous system effects, gastrointestinal disturbances, and cardiac arrhythmias, requiring an immediate visit to a healthcare facility. Lastly, this medication is not recommended for children and adolescents as safety and efficacy have not been established.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, anorexia, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, hypersensitivity, panic attacks, confusion, aggression, depersonalization, hallucinations, mania, suicidal thoughts, suicidal behavior, insomnia, drowsiness, dizziness, paresthesia, tremors, taste disorders, sleep disorders, syncope, serotonin syndrome, movement disorders, motor dysfunction, convulsions, psychomotor agitation, akathisia, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, prolonged QT interval on ECG, polymorphic ventricular tachycardia, orthostatic hypotension, sinusitis, yawning, epistaxis, nausea, diarrhea, constipation, vomiting, polydipsia, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, petechiae, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation disorders, erectile dysfunction, uterine hemorrhage, menorrhagia, galactorrhea, postpartum hemorrhage, priapism, fatigue, fever, edema, headache, dry mouth, abdominal pain, dyspepsia, enteritis, sensory disturbances, cough, asthma, respiratory distress, fractures, palpitations, hypertension, sedation, frequent urination, tremor, abdominal discomfort, anxiety, insomnia, visual hallucinations, retrograde anxiety, seizure, mania, changes in blood sugar control, anxiety, agitation, panic disorder, insomnia, excitement, hostility, aggression, impulsivity, akathisia, hypomania, mania, withdrawal symptoms, dizziness, sleep disorders, anxiety, tremors, confusion, sweating, headache, diarrhea, palpitations, emotional instability, hypersensitivity, visual impairment, hypokalemia, hypomagnesemia, newborn behavioral disorders, neonatal withdrawal effects, neonatal respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulties, vomiting, hypoglycemia, muscle hypertonia, muscle hypotonia, hyperreflexia, tremor, agitation, hypersensitivity, narcolepsy, persistent crying, drowsiness, sleep disturbances, persistent pulmonary hypertension in newborns, increased risk of postpartum hemorrhage, dizziness with overdose, tremors, agitation, serotonin syndrome, convulsions, coma, hypotension, arrhythmia

This medication is sensitive to light and should be stored in a container that does not allow light in. Additionally, it is best to store the medication at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness over time.

Appearance

White rectangular film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle